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Abstract: Many neurodegenerative diseases are associated, at least in part, to an inflammatory
process in which microglia plays a major role. The effect of the triglyceride form of the omega-3
polyunsaturated fatty acid docosahexaenoic acid (TG-DHA) was assayed in vitro and in vivo to assess
the protective and anti-inflammatory activity of this compound. In the in vitro study, BV-2 microglia
cells were previously treated with TG-DHA and then activated with Lipopolysaccharide (LPS)
and Interferon-gamma (IFN-γ). TG-DHA treatment protected BV-2 microglia cells from oxidative
stress toxicity attenuating NO production and suppressing the induction of inflammatory cytokines.
When compared with DHA in the ethyl-ester form, a significant difference in the ability to inhibit
NO production in favor of TG-DHA was observed. TG-DHA inhibited significantly splenocyte
proliferation but isolated CD4+ lymphocyte proliferation was unaffected. In a mice model of
autoimmune encephalomyelitis (EAE), 250 mg/kg/day oral TG-DHA treatment was associated with
a significant amelioration of the course and severity of the disease as compared to untreated animals.
TG-DHA-treated EAE mice showed a better weight profile, which is a symptom related to a better
course of encephalomyelitis. TG-DHA may be a promising therapeutic agent in neuroinflammatory
processes and merit to be more extensively studied in human neurodegenerative disorders.
Keywords: docosahexaenoic acid; microglia; omega-3 polyunsaturated fatty acid; oxidative stress;
anti-inflammatory process; EAE model
1. Introduction
Nerve injury and neuroinflammation can result from a number of physical, chemical, infectious,
and immunological causes. Although, in general, microglia cells play a beneficial role in various
aspects of maintenance and repair of the central nervous system (CNS), they also contribute to CNS
damage through several pathways involved in neuroinflammatory or autoimmune conditions, such
as secretion of inflammatory cytokines (e.g., interleukin (IL)-6, tumor necrosis factor (TNF)-α, IL-1)
and nitric oxide (NO) [1]. Furthermore, microglia cells in the presence of T-cells are the main factor
responsible for the induction of the immune response in brain, where they play a role similar to that
of dendritic cells in the periphery in the recognition and presentation of self and foreign antigens
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via phagocytic activity [2,3]. Non-activated microglia do not express or express low levels of major
histocompatibility complex (MHC) class I/II proteins, and therefore act as weak antigen presenting
cells (APCs). However, activated microglia cells rapidly express MHC class I/II molecules and
become effective APCs. Also, microglia may contribute to the pathology of neurological disorders
via non-inflammatory mechanisms, for instance, via signaling pathways that accelerate neuronal
apoptosis or by altering amyloid-beta metabolism. When an inflammatory process occurs, T-cells
cross the blood-brain barrier, thanks to some specialized surface markers, and are rapidly activated
by microglia, which acts as APCs displaying antigens. By these various mechanisms, microglia have
been implicated in the progression or adverse outcomes of a number of diseases or injuries, including
Alzheimer’s disease (AD), multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), Parkinson’s
disease (PD), stroke, and variant Creutzfeldt-Jakob disease [1,4,5].
Different animal models of neuroinflammation and neurodegeneration have been developed [6–11].
Induction of autoimmune encephalomyelitis (EAE) in susceptible strains of mice can be achieved by using
proteolipid protein (PLP), myelin basic protein (MBP), myelin oligodendrocyte glycoprotein (MOG),
or peptides corresponding to the encephalitogenic portions of these proteins, together with a potent
adjuvant and bacterial toxin to induce a strong immunological activation of myelin antigen-specific
T-cells and the breakdown of peripheral tolerance.
Mice models of EAE, in spite of some common traits with ALS, have been more frequently
associated with MS, since many peculiar pathologies observed in the CNS of mice with EAE bear strong
similarities with those found in the CNS of MS patients [12]. Both EAE and MS are demyelinating
autoimmune disorders of the CNS mediated by CD4+ T-cell activation associated with demyelinating
lesions, which are characterized by mononuclear cell infiltration (T-cells, B-cells, monocytes,
macrophages, and neutrophils) due to chemokine production by the pathogenic T-cells [13–15].
Activated T-cells express integrins that enable them to cross the blood–brain barrier [16]. In the brain,
T-cells are reactivated by microglia cells acting as APCs [17], which with other inflammatory cells
leads to the expression of proinflammatory cytokines (Interferon-gamma (IFN-γ), IL-17, Granulocyte
Macrophage Colony-Stimulating Factor (GM-CSF), and TNF-α), some of which can directly injure
nervous tissue and are largely responsible for destruction of the myelin-sheathed axonal tracts and the
development of lesions.
In the EAE model, CNS inflammatory cell infiltration is accompanied by the activation of microglia
and the release of proinflammatory cytokines associated with oxidative stress and apoptosis of neuronal
tissue [18,19]. The presenting clinical episode of EAE is characterized by an ascending hind limb
paralysis beginning in the tail and spreading to the hind limbs and forelimbs. This is considered
an acute-phase of the disease and is preceded by pronounced weight loss.
Furthermore, the discovery of the role for activated microglia in all these neuroinflammatory
diseases has led to their emergence as a target for therapeutic intervention, either to prevent or treat
neuroinflammatory disease such as chronic neurodegenerative disorders, or to improve outcomes after
acute episodes or injuries [20,21]. A way of controlling neuroinflammation is by inhibition of microglial
activation. Multiples stimuli are able to activate microglia, but it seems that all of them are mainly
dependent of the activation of mitogen-activated protein kinase (MAPK) controlled pathways [22].
Accordingly, MAPK-inhibiting drugs may be a promising target for neuroinflammatory diseases.
It has been shown that agonists of peroxisome proliferator-activated receptor-gamma (PPAR-γ)
inhibited the production of NO, proinflammatory cytokines (IL-1β, IL-6, and TNF-α), and chemokine
monocyte chemotactic protein-1 (MCP-1) in microglia and astrocytes [23]. Oral treatment with
pioglitazone, a PPAR-γ agonist, diminished motor neuron loss, enhanced motor performance, delayed
weight loss, and also reduced iNOS, NF-κB, and 3-nitrotyrosine levels in spinal cords, prolonging
survival by 13% of G93A SOD (transgenic mouse model of ALS) when compared with an untreated
control littermate counterparts, suggesting the therapeutic potential of PPAR-γ agonists in human
neuroinflammatory diseases [24,25].
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In spite of the availability of approved drugs for the treatment of patients with neuroinflammatory
disorders, they often have a limited efficacy and a narrow therapeutic index. Thus, there is an urgent
need to develop new drugs for the treatment of these patients. Omega-3 fatty acids and especially
docosahexaenoic acid (DHA) are natural products which can be taken as dietary supplements, and
have been shown to act throughout nuclear PPAR-γ receptors on dendritic cells, modulating their
inflammatory activity [26] and converting dendritic cells in poor stimulators of antigen-specific T-cells
in terms of proliferation and Th1/Th17 differentiation [3]. Furthermore, these fatty acids have shown
modulation of the inflammatory properties of activated microglia [11,27–29] and amelioration of
neurodegenerative diseases involving neuroinflammation [30,31]. The objective of this study was to
determine the capacity of the triglyceride form of natural DHA (TG-DHA), which has shown improved
bioavailability [32,33], as compared to the ethyl ester form to modulate the proinflammatory activity of
in vitro cultured microglial cells, as well as to assess the effect of TG-DHA in the course of the disease
in a mice model of EAE [12].
2. Materials and Methods
2.1. Reagents
Triglyceride of docosahexanoic acid (TG-DHA) obtained by enzymatic synthesis was kindly
supplied by Brudy Technology (Barcelona, Spain). For the ethyl ester of DHA (EE-DHA) Omacor
(Pronova BioPharma Norge AS, N-1327 Lysaker, Norway) was used. DHA compounds were prepared
in dimethyl sulfoxide (DMSO, Sigma-Aldrich, St. Louis, MO, USA) and diluted in the culture media
immediately before cell treatment, being added to the cells at DMSO concentration of 0.5%.
2.2. Cell Culture and Treatment
BV-2 cells were cultured in RPMI-1640 medium (Gibco Invitrogen, Paisley, Scotland, UK)
supplemented with 10% Fetal Bovine Serum (FBS) and 0.1% penicillin-streptomycin at an initial density
of 5 × 104 cells/mL, at 37 ◦C in a 5% CO2. Treatments with TG-DHA (1–20 µM) or EE-DHA (10–20 µM)
were performed 30 min before stimulation with Lipopolysaccharide (LPS) 100 ng/mL and IFN-γ
50 pg/mL one day after cells were seeded. Control cells were cultured at the same final concentration
of vehicle as DHA-treated cells. Culture supernatants were collected 24 h after LPS/IFN-γ stimulation
and stored at −20 ◦C until assayed for nitrites and TNF-α quantification. Cell viability was determined
after treatment with the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT)
reduction method.
2.3. Nitrite and Cytokine Quantification
Nitrite levels were quantified by the Griess reaction [34]. Briefly, 25 µL of Griess reagent A
(sulfanilamide) and 25 µL of reagent B (N-1-naphthylethylene-diamine) were mixed with 50 µL of
culture supernatants in a 96-well plate. After 10 min at 23–25 ◦C, color development was measured
at 540 nm on a microplate reader (BioTek ELX800, BioTek Instruments Inc., Winoosky, VT, USA).
A sodium nitrite standard curve was used to determine the nitrite concentration. IL-6 released into
the culture medium was quantified using an Enzyme-Linked Immuno Sorbent Assay (ELISA) kit
specific for mouse IL-6 (Mouse IL-6 Ready-SET-Go!®, eBioscience, San Diego, CA, USA) and TNF-α
with a specific murine TNF-α ELISA kit (Murine TNF-α ELISA Development Kit, Peprotech, Rocky
Hill, NJ, USA) following the manufacturer’s instructions.
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2.4. Cell Viability: 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT)
Reduction Method
Cell viability was established by MTT reduction assay. Briefly, 96 microplate wells were filled
with MTT (Sigma-Aldrich) at a final concentration of 0.5 mg/mL per well and incubated at 37 ◦C,
then DMSO was added and cells were gently resuspended. Absorbance was read at 560 and 620 in
a microplate reader (BioTek ELX800, BioTek Instruments Inc., Winoosky, VT, USA).
2.5. Mice
Female C57BL/6J mice (8 to 10 weeks old) purchased from Charles River (Sulzfeld, Germany)
were handled according to European legislation (86/609/EEC) as previously described [34]. All the
experiments and procedures were approved by the Ethics Committee of the University of Barcelona
under the supervision of the Generalitat of Catalunya, Spain.
2.6. EAE Induction and Treatment
EAE was induced by immunization with >95% pure synthetic MOG35-55 peptide (rat MOG35-55,
MEVGWYRSPFSRVVHLYRNGK, EspiKem Srl, Florence, Italy). Mice were injected subcutaneously
at one side of the flank with 100 µL solution containing 150 µg of rat MOG in complete Freund’s
adjuvant (Sigma-Aldrich) and 5 mg/mL Mycobacterium tuberculosis H37Ra (Difco Laboratories, Detroit,
MI, USA). Forty-eight hours after MOG injection, 150 ng pertussis toxin (Sigma-Aldrich) in 100 µL
PBS were injected intraperitoneally. The animals were monitored every other day for the development
of clinical symptoms, which typically become evident between 12 and 20 days after immunization.
Once the disease had developed, mice were assessed daily for changes in severity. Signs of EAE were
scored daily on a 0 to 6 scale using the following criteria: 0, no clinical signs; 1, distal limp tail; 1.5,
complete limp tail; 2, mild paraparesis of the hind limbs, unsteady gait, and impairment of righting
reflex; 3, moderate paraparesis, partial hind limb paralysis, voluntary movements still possible, and
ataxia; 4, paraplegia and forelimb weakness; 5, tetraparesis; 6, moribund state. Mice were treated daily
by oral administration of 50 mg/kg TG-DHA, 250 mg/kg TG-DHA, or vehicle (0.3% DMSO in water)
over a total of 56 days, with treatment beginning 15 days prior to EAE induction. At this time mice
were euthanized under deep anesthesia to obtain blood and tissues to perform analysis described
below. No treatment-related adverse effects were observed in any of either healthy or EAE-induced
mice following standard criteria [35]. Experiments were performed with groups (n = 10) of C57BL/6J
healthy untreated mice (healthy untreated group), healthy DHA-treated mice (healthy DHA-treated
group), EAE-induced untreated mice (EAE untreated group), and EAE-induced DHA-treated mice
(EAE-DHA-treated group) as indicated. The groups of mice were randomized. No previous selection
was made for any characteristics, such as weight, size, etc.
2.7. Mouse Splenocytes and CD4+ T-Cells Preparation
Splenocytes were isolated from the spleens of female C57BL/6J mice. Cells were flushed out from
the spleens gently using a syringe plunger with PBS and then centrifuged (×1000 rpm, 4 ◦C). The pellet
was resuspended and left 5 min on ice in ACK lysing buffer (Invitrogen, Eugene, OR, USA) to remove
erythrocytes. After further centrifugations, cells were resuspended in 10 mL of complete medium
RPMI (Invitrogen) supplemented with 10% Fetal Bovine Serum (FBS, Invitrogen), Hepes 10 mM
(Invitrogen), sodium pyruvate 1 mM (Invitrogen), non-essential amino acids 1% (Sigma-Aldrich), and
50 µM β-mercaptoethanol (Sigma-Aldrich).
CD4+ T-cells were isolated using Dynabeads FlowComp Mouse CD4 kit (DYNAL, Invitrogen)
following the manufacturer’s instructions. After isolation, cells were counted and the viability
was determined by trypan blue exclusion, while the purity for CD4+ cells (>92%) was assessed
by fluorescence activated cell sorting (FACS) (Gallios BD Bioscience).
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2.8. Proliferative Response of Lymphocytes
Proliferation assay was carried out by plating 2 × 105 cells/well in 96-well plates followed by
exposure to stimulus anti-CD3 (KT3, coated at 1 µg/mL; Serotec, Oxford, England, UK) and anti-CD28
(37.51, coated at 2.5 µg/mL; eBioscience, San Diego, CA, USA) for 72 h. Cell proliferation was
determined by colorimetric bromodeoxyuridine (BrdU) cell proliferation kit (Calbiochem, Darmstadt,
Germany) following the manufacturer’s instructions. In brief, 20 µL of BrdU labelling solution diluted
1:2000 in a culture medium was added to each well for the last 18 h of culture. After removing the
medium, cells were fixed, and the anti-BrdU peroxidase working solution was added to each well
and incubated for 1 h at room temperature. Following several washes, the substrate solution was
added, color was developed, and absorbance was measured with a microplate reader at 450 nm.
Proliferation rate was calculated as the absorbance of cells in the presence of anti-CD3-CD28 divided
by the absorbance of cells in the absence of antibodies.
2.9. Determination of Tissue Fatty Acids Profile
To check absorption of fatty acids by mice, the fatty acid composition of plasma lipids was
assessed by gas chromatography. Plasma total lipids were extracted by the method of Bligh and Dyer
with chloroform: methanol (2:1, v:v). Methyl esters of fatty acids were obtained by transesterification
with boron trifluoride in methanol at 80 ◦C for 60 min. An aliquot containing the methyl esters of
fatty acids was analyzed by gas chromatography (Hewlett-Packard model 5890) on a 30 m RTX-2330
column (Restek, Bellefonte, PA, USA) with an internal diameter of 0.25 mm equipped with a flame
ionization detector. The carrier gas was helium at a pressure of 105 kPa. For the total separation of the
different compounds, two temperature settings were established: 140 ◦C–200 ◦C at 3 ◦C/min or in two
stages of 140 ◦C–180 ◦C at 4 ◦C/min and 180 ◦C–210 ◦C at 2 ◦C/min. The temperature of the injector
and detector was 260 ◦C. The linear response of the detector was tested periodically with standard
mixtures. Typically, two internal standards with different molecular weight (13:0 and 23:0 or 27:0) were
used. Peaks were integrated with an integrator D-2500 (Hitachi Ltd., Tokyo, Japan) and identified by
comparison of retention times with standards. When necessary, the identification may be confirmed by
mass spectrometry (Hewlett-Packard detector model 5970B) at an ionization potential of 70 eV.
2.10. Statistical Analysis
Statistical analysis was performed with the GraphPad Prism Version 6.01 software (San Diego,
CA, USA). In vitro experimental analyses were performed using ANOVA test followed by Bonferroni’s
multiple comparison post-hoc test. To analyze the effect of EAE treatment on clinical signs and weight,
day-by-day comparison was performed between treated and control animals using the Kruskal-Wallis
and ANOVA test, respectively. Data are expressed as the mean ± standard error of the mean (SEM)
unless otherwise stated. Statistical significance was set at p < 0.05.
3. Results
3.1. DHA Increased BV-2 Cells Viability
Usually DHA treatment has been associated with induction of apoptosis or cell death by other
mechanisms in many cells [36,37]. However, BV-2 microglia cells treated in vitro with TG-DHA showed
an increase in viability, both in basal activity (Figure 1B) and when activated with lipopolysaccharide +
IFN-γ (L + I) (Figure 1A,C), with the highest increase at DHA 20 µM (Figure 1B,C), but with similar
results in cells treated with 1, 5, or 10 µM (Figure 1C). These increases, however, were not statistically
significant. DHA in the ethyl ester form (EE-DHA) also slightly increased BV-2 microglial cells viability
in both conditions but to a lesser extent than TG-DHA.
Nutrients 2017, 9, 681 6 of 15
Nutrients 2017, 9, 681 6 of 14 
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triglyceride (TG)-DHA 20 µM (right) or L + I activated but untreated (center). Controls not activated 
and untreated are presented in the left picture. BV-2 cells were treated with DHA and then 
stimulated (C) or not (B) with lipopolysaccharide + Interferon-gamma (L + I) for 24 h. Cell viability 
was examined by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) 
reduction assays and the results were expressed as percentage of surviving cells over untreated 
control cells (Ctrl). Each value indicates the mean ± standard error of mean (SEM) values obtained in 
each of the three independent experiments. DHA was added in the triglyceride form (TG-DHA) or 
in the ethyl ester form (EE-DHA). In spite of the tendencies observed in favor of TG-DHA, 
differences were not statistically significant. 
3.2. DHA Attenuated NO Production and Suppressed Induction of Inflammatory Cytokines in LPS-
Stimulated BV-2 Microglia Cells 
It has been described that nitric oxide (NO), depending of the concentrations and 
pathophysiological conditions, is able to regulate cell proliferation, cell cycle arrest, and apoptosis 
in an opposite way. Thus, at relatively low concentrations NO may induce cell proliferation and 
anti-apoptotic activity, but at higher concentrations NO seems to activate pathways which induce 
cell cycle arrest, mitochondria respiration, senescence, or apoptosis [36–38]. 
At doses from 5 to 20 µM, TG-DHA dramatically reduced NO production of L + I activated 
BV-2 microglia cells in a concentration-dependent manner (Figure 2A). Interestingly, TG-DHA at 1 
µM increased, although not significantly, NO production with respect to controls, suggesting a 
threshold mechanism. 
The effect of TG-DHA in the ability to inhibit NO production was significantly higher as 
compared with EE-DHA (Figure 2D). 
TG-DHA also induced a significant inhibition of the production of inflammation-associated 
cytokines (TNF-α and IL-6) by L + I-activated BV-2 microglia cells at concentrations ranging from 1 
to 20 µM (Figure 2B,C) but differences between TG-DHA and EE-DHA were not observed (Figure 
2E). Taking into account the increase of viability of the BV-2 microglia cells observed above (Figure 
1), the inhibition of cytokine production should be considered even higher. 
Figure 1. Effect of docosahexaenoic acid (DHA) on BV-2 microglial cells viability. (A) Optical
microscopy pictures of BV-2 microglia cells cultures activated with L + I and treated with triglyceride
(TG)-DHA 20 µM (right) or L + I activated but untreated (center). Controls not activated and untreated
are presented in the left picture. BV-2 cells were treated with DHA and then stimulated (C) or not
(B) with lipopolysaccharide + Interferon-gamma (L + I) for 24 h. Cell viability was examined by
3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) reduction assays and the
results were expressed as percentage of surviving cells over untreated control cells (Ctrl). Each value
indicates the mean ± standard error of mean (SEM) values obtained in each of the three independent
experiments. DHA was added in the triglyceride form (TG-DHA) or in the ethyl ester form (EE-DHA).
In spite of the tendencies observed in favor of TG-DHA, differences were not statistically significant.
3.2. DHA Attenuated NO Production and Suppressed Induction of Inflammatory Cytokines in LPS-Stimulated
BV-2 Microglia Cells
It has been described that nitric oxide (NO), depending of the concentrations and
pathophysiological conditions, is able to regulate cell proliferation, cell cycle arrest, and apoptosis
in an opposite way. Thus, at relatively low concentrations NO may induce cell proliferation and
anti-apoptotic activity, but at higher concentrations NO seems to activate pathways which induce cell
cycle arrest, mitochondria respiration, senescence, or apoptosis [36–38].
At doses from 5 to 20 µM, TG-DHA dramatically reduced NO production of L + I activated
BV-2 microglia cells in a concentration-dependent manner (Figure 2A). Interestingly, TG-DHA at
1 µM increased, although not significantly, NO production with respect to controls, suggesting
a threshold mechanism.
The effect of TG-DHA in the ability to inhibit NO production was significantly higher as compared
with EE-DHA (Figure 2D).
TG-DHA also induced a significant inhibition of the production of inflammation-associated
cytokines (TNF-α and IL-6) by L + I-activated BV-2 microglia cells at concentrations ranging from 1 to
20 µM (Figure 2B,C) but differences between TG-DHA and EE-DHA were not observed (Figure 2E).
Taking into account the increase of viability of the BV-2 microglia cells observed above (Figure 1), the
inhibition of cytokine production should be considered even higher.
Nutrients 2017, 9, 681 7 of 15
Nutrients 2017, 9, 681 7 of 14 
 
 
Figure 2. Treatment with DHA protected LPS + IFN-γ L + I-activated BV-2 microglia cells. Cells 
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or IL-6 (C) by Enzyme-Linked Immuno Sorbent Assay (ELISA). The effect of TG-DHA on BV-2 cells 
was compared with EE-DHA (10–20 µM) and assayed for nitrites (D) or TNF-α (E) under the same 
conditions described above. All experiments were performed in triplicate and repeated at least three 
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wells. * = p < 0.05; ** = p <0.01; *** = p < 0.005. 
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doses of TG-DHA tested (1–20 µM), the viability of splenocytes was slightly higher (but not 
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Figure 2. Treatment with DHA protected LPS + IFN-γ L + I-activated BV-2 microglia cells. Cells
were treated with TG-DHA before stimulation ith L+I. Culture supernatants of BV-2 cells were
collected 24 h after L + I stimulation and for nitrites by the Griess reaction (A) or TNF-α (B)
or IL-6 (C) by Enzyme-Linked Im uno Sor ssay (ELISA). The ffect of TG-DHA on BV-2 cells
was compared with EE-DHA (10–20 µM) a ed for nitrites (D) or TNF-α (E) under the same
conditions described above. All experime ts ere erformed in triplicate and repeated at least three
times. Control wells contained the same final concentration of vehicle as compound-containing wells.
* = p < 0.05; ** = p <0.01; *** = p < 0.005.
3.3. Effects of DHA on Splenocyte Viability and Proliferation after Lymphocyte Stimulation
Mice splenocytes or purified CD4+ T cells were isolated and cultured in the presence or absence
of TG-DHA. No toxicity was observed on splenocytes or CD4+ T cells. By contrast, at the doses
of TG-DHA tested (1–20 µM), the viability of splenocytes was slightly higher (but not statistically
significant) (Figure 3).
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Figure 3. Effects of DHA in splenocyte and CD4+ T cells viability. Splenocytes (A) and CD4+ T cells
(B) isolated from spleens of mice fed with a control diet were cultured ex vivo in the presence of DHA.
Cell viability was examined by MTT reduction assays and the results were expressed as percentage of
surviving cells as compared to control cells (Control). Each value indicates the mean ± SEM of results
obtained in three independent experiments. In spite of the tendencies observed in favor of TG-DHA,
no statically significant differences were found.
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When splenocytes or CD4+ T cells were induced to proliferate by culture in anti-CD3/anti-CD28
coated plates, at all doses tested, TG-DHA inhibited significantly anti-CD3/anti-CD28-stimulated
splenocyte proliferation (Figure 4A). However, none of the doses tested affected proliferation of
isolated CD4+ lymphocytes stimulated by anti-CD3/anti-CD28 (Figure 4B), suggesting a different
regulatory mechanism [39,40].
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SFA 31.70 ± 0.96 31.70 ± 0.49 47.53 ± 4.23 50.25 ± 6.89 
MUFA 16.97 ± 1.19 16.23 ± 1.35 13.27 ± 0.57 14.54 ± 0.81 
PUFA 51.33 ± 1.12 52.07 ± 1.36 39.20 ± 4.74 35.21 ± 7.60 
PUFA n-6 47.68 ± 1.36 47.60 ± 1.24 32.01 ± 4.43 29.93 ± 5.75 
PUFA n-3 3.65 ± 1.08 3.87 ± 0.91 6.55 ± 1.12 5.28 ± 1.93 
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monounsaturated fatty acid; PUFA: polyunsaturated fatty acids; n-6: omega-6; n-3: omega-3; C22:6 
omega-3: DHA. 
Figure 4. Effect of DHA on splenocytes and CD4+ T cells proliferation after anti-CD3/anti-CD28
lymphocyte stimulation. Splenocytes (A) and purified CD4+ T-cells (B) were isolated from mice and
cultured in presence or absence of TG-DHA (1–20 µM). Proliferation assay was carried out after 72 h
and determined using a commercial colorimetric bromodeoxyuridine (BrdU) cell proliferation kit.
Proliferation rate was calculated as the absorbance of cells in the presence of anti-CD3-CD28 divided
by the absorbance of cells in the absence of antibodies. * = p < 0.05; ** = p < 0.01; *** = p < 0.001.
3.4. Effect DHA Dietary Supplementation on Fatty Acid Profile in Mice Tissues
No significant differences were observed in plasma and red blood cell (RBC) membrane (Table 1)
with respect to the profile and level of saturated, monounsaturated, polyunsaturated, omega-6, or
omega-3 fatty acids in the healthy untreated and the EAE untreated groups. This demonstrated that
the fatty acid profile is not dependent of the healthy status of the animals, but the diet they are fed.
Table 1. Fatty acid composition of total lipids from plasma and red blood cell (RBC) membrane isolated
from healthy untreated (Ctl) animals or with autoimmune encephalomyelitis (EAE)-induced disease.
% of Total Fatty Acids
Total Fatty Acids
Plasma RBC
Ctl (n = 7) EAE (n = 7) Ctl (n = 7) EAE (n = 7)
SFA 31.70 ± 0.96 31.70 ± 0.49 47.53 ± 4.23 50.25 ± 6.89
MUFA 16.97 ± 1.19 16.23 ± 1.35 13.27 ± 0.57 14.54 ± 0.81
PUFA 51.33 ± 1.12 52.07 ± 1.36 39.20 ± 4.74 35.21 ± 7.60
PUFA n-6 47.68 ± 1.36 47 6 1.24 32.01 ± 4.43 29.93 ± 5.75
PUFA n-3 3.65 ± 1.08 3.87 ± 0.91 6.55 ± 1.12 5.28 ± 1.93
n-6/n-3 ratio 14.17 ± 2.22 11.07 ± 2.25 5.83 ± 0.74 6.09 ± 1.29
C22:6 n-3 3.01 ± 0.48 2.96 ± 0.79 4.83 ± 0.83 3.39 ± 1.08
Data are presented as mean ± standard deviation (SD). SFA: saturated fatty acid; MUFA: monounsaturated fatty
acid; PUFA: polyunsaturated fatty acids; n-6: omega-6; n-3: omega-3; C22:6 omega-3: DHA.
Mice fed orally with TG-DHA at 50 or 250 mg/kg/day for 56 days did not show any toxic effect.
In the healthy and EAE groups, these treatments showed a logical upward trend in the level of DHA
and omeg fatty acids, and a decrease in the omega-6 to omega-3 fatty acid ratio in plasma, RBC
membrane, and spleen as compared to untreated animals in both the healthy group (Figure 5A,B,D)
and in the EAE model (Figure 5E,F,H). The observed differences were not statistically significant, but
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logical due to diet, in treated with respect to untreated animals. However, in both groups, a null
increase in the level of DHA or omega-3 fatty acids in the brain tissue regardless of the dose was
observed (Figure 5C,G), possibly because it is a more omega-3 saturated tissue. Between-group
differences were not statistically significant, which means that, with little variations, the bioavailability
of TG-DHA was the same in all groups despite the health status.
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3.5. Dietary DHA Showed a Beneficial Effect on EAE Clinical Course
To assess the effects of essential fatty acids on the clinical course of the EAE mice model, animals
were treated with oral TG-DHA 50 or 250 mg/kg/day (n = 10 for each group) during 15 days
before induction of encephalomyelitis and over the next 41 days (total days of treatment 56). The
EAE-untreated group were animals without TG-DHA treatment. EAE disease severity scoring and
weight measurement were performed daily.
Oral TG-DHA treatment ameliorated EAE course and severity (Figure 6A) as compared to
EAE-untreated animals, and especially at 250 mg/kg/day the effect was highly significant from day
15 of treatment (Figure 6A). In the same way, EAE mice treated with TG-DHA versus EAE-untreated
animals also showed a better weight profile from day 30 of treatment (Figure 6B), a symptom associated
with a better course of the disease. This effect was mainly observed with the 250 mg/kg/day dose
(Figure 6B).
No adverse effects associated with the treatment were observed. Moreover, DHA-treated animals
showed not only amelioration in the EAE neurological scoring results, but also a better aspect and
lower external signs of discomfort. At the end of the study, three mice had died in the EAE-untreated
group and only one in the EAE-DHA- treated group.
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Figure 6. Dietary DHA improved the outcome of experimental autoimmune encephalomyelitis.
EAE-induced C57BL/6 mice were fed with a normal diet in an untreated group (n = 10, ) or a normal
diet supplemented with TG-DHA 50 (n = 10, ) or 250 mg/kg/day (n = 10, N) for 56 days. Mice
were immunized with MOG35–55 as described in the Methods section. Kinetics of mean clinical
score (A) and percentage change in weight (B) were controlled daily and compared day-by-day with
the unt ated grou . Survival at the end of the observation period was also assessed. * = p < 0.05,
** = p < 0.01.
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4. Discussion
Neuroinflammatory processes due to a variety of causes ranging from infectious diseases
to chemical toxicity injuries are the underlying pathophysiological mechanism of many
neurodegenerative disorders in which microglia cells play an important role. In this study, the
triglyceride of omega-3 polyunsaturated fatty acid docosahexaenoic acid (TG-DHA) has been assayed
in vitro and in vivo as compared to the DHA ethyl ester form, to determine its capacity to protect
cells from oxidative stress injury and inflammatory cytokine damage activity. The beneficial effects of
TG-DHA have also been studied in a mice model of EAE.
The role of omega-3 polyunsaturated fatty acid (n-3 PUFA) in different cellular systems is still
controversial, ranging from death induction by means of oxidative stress products [36,37,41] to
protective activity increasing survival and anti-oxidative stress [42–46]. However, the anti-inflammatory
activity of omega-3 PUFA and especially of DHA has been reported for a long time as a general behavior
in dendritic [26,30,47–49] and microglia cells [11,27–29]. Moreover, treatment with DHA has been
reported to ameliorate neurodegenerative diseases involving neuroinflammation [30,31], including
EAE [3]. In the present study, we demonstrated that with respect to EE-DHA, TG-DHA treatment shows
an increased protection on BV-2 microglia cells activated with LPS and IFN-γ from toxicity, increasing
viability, attenuating NO production, and suppressing the induction of pro-inflammatory cytokines
(Figures 1 and 2). This behavior could be related to the better bioavailability of the TG-DHA compared
to EE-DHA [32,33].
TG-DHA significantly inhibited mice splenocyte proliferation but did not affect proliferation of
isolated CD4+ lymphocytes cultured in anti-CD3/anti-CD28 coated plates (Figure 4). This fact suggests
the possibility of an indirect mechanism in which the anti-proliferative effects of TG-DHA could be
associated with a modulation of the monocyte-dendritic cell antigen presentation activity, as observed
previously [26]. However, T-cell inhibition has been confirmed by other authors [39,40], suggesting that
anti-proliferative effects of TG-DHA are probably associated with a macrophage/monocyte modulation
instead of a direct activity on lymphocytic immunomodulation. Although molecular mechanisms are
not exclusive of the myeloid cells and omega-3 fatty acids could inhibit T-lymphocytes through several
mechanisms (like PPARγ upregulation and activation which induce Treg proliferation) [25,50,51],
at the conditions of the present assay, there probably was not enough time to develop regulatory T-cells
to induce CD4+ T-cell inhibition (Figure 4B).
No differences in the profile and level of fatty acids from plasma and RBC membranes of healthy
animals were observed in comparison with those from the mouse EAE model (Table 1). When mice
were fed with a supplement of 50 to 250 mg/kg/day of TG-DHA, a slightly but upward trend of the
level of DHA and the omega-3 in the peripheral tissues (plasma, RBC, and spleen) was observed in
a dose-dependent manner, both in healthy animals and in those with a EAE (Figure 5). However, no
changes or almost undetectable changes were observed in the CNS tissues (Figure 5).
In a mouse model of EAE, when comparing untreated animals with high and low doses of
TG-DHA treatment, it was observed that high doses significantly ameliorated the clinical course and
severity of disease in a dose and time dependent manner (Figure 6), in relation to both the EAE clinical
score and weight profile (a symptom associated with a better course of the disease). Our results with
TG-DHA confirm and improve previous results from Kong W. et al. [3], demonstrating that TG-DHA
with a DHA high content (>70% of total fatty acids) is a more effective treatment and improves
the outcome and disease evolution in the mouse model of EAE. Our data suggest that prophylactic
administration of TG-DHA confers significant protection against the development of EAE at clinical
and molecular levels.
Among the strengths of this study were the approach of the problem with the types of cells
involved in the neuroinflammation processes and their phenotypic and functional changes, the
comparative study of different doses of DHA in its different chemical forms and with a high
content in DHA, the strict control of the animals involved in the study, and the assessment of the
variations in the composition of the content of fatty acids in cell membranes and plasma. However,
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some limitations in this work remain. Further, there is a paucity of studies on the mechanisms
of DHA on neuroinflammation pathways in vivo. It is hypothesized that omega-3 PUFA are
anti-inflammatory via their enzymatically-derived metabolites, however, comprehensive lipidomics
profiling during neuroinflammation has not been reported yet and the pathways that they mediate
should be investigated. Nevertheless, the results presented here advance our understanding of the
anti-inflammatory effect of DHA in EAE, and further studies should be conducted to address the
concerns raised.
5. Conclusions
We conclude that DHA, a natural product that can be taken as a dietary supplement, showed
no toxic effects on microglial cells in the in vitro studies as well as the in vivo studies of mice treated
with high DHA doses for a long period of time. In the supplement used in this study, DHA was
present in the form of triglycerides, nutrients naturally recognized by the body, to guarantee high
digestibility and intestinal absorption. Furthermore, TG-DHA modulates the in vitro activity of
microglia cells and T-cells, suggesting a neuronal cell protection from cytotoxic insults. In the EAE
mouse model, treatment with TG-DHA had a beneficial effect on the clinical course and severity of
autoimmune encephalomyelitis. The beneficial and protective effects of TG-DHA are mediated, at
least in part, through oxidant effects and by modulating the autoimmune responses within the CNS
as well as at the systemic level. According to these results, TG-DHA may be a promising nutritional
immunomodulating agent in neuroinflammatory processes, suggesting potential favorable effects in
human neurodegenerative disorders.
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